52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
Go back to 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 65.70 +4.72 (7.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $60.98 | 52 Week High | $19.98 | |||
| Open | $62.30 | 52 Week Low | $10.52 | |||
| Day High | $66.60 | P/E | N/A | |||
| Day Low | $62.30 | EPS | $-1.45 | |||
| Volume | 1,404,613 | |||||
